Marilyn Tan, MD, Clinical Assistant Professor, Department of Medicine, Division of Endocrinology, Gerontology, and Metabolism Stanford University School of Medicine
Research Description: Dr. Tan’s serves as the principal investigator for a phase 2 trial assessing the role of glucagon like peptide 1 (GLP1) in patients with post bariatric hypoglycemia. The study involves a dose escalation trial to assess efficacy and pharmacokinetics for Exendin (9-39). Eiger Pharmaceutical company sponsored this study, and it is currently at 50% completion, with an expected completion date of April 2017. She is also the site primary investigator for the HARMONY outcomes trial with albiglutide in patients with type 2 diabetes and high cardiovascular risk. The aim is to assess for long term cardiovascular safety and possible benefits with GLP1 agonists. This study is sponsored by Glaxo Smith Kline. Dr. Tan was a co-investigator for the GI Dynamics Endosleeve trial assessing improvement in glycemic control with the Endo Barrier gastrointestinal liner system in obese patients with type 2 diabetes. This study is currently on hold by the FDA. Other collaborations include a clinical study of breath acetone measurements for patients with ketosis or ketoacidosis, a study of the immune response to pre-proinsulin in human type 1 diabetes, and integrative personal omics profiling for dynamic molecular phenotypes monitoring and medical risks assessment.
Selected relevant publications (Stanford DRC Members in BOLD):
1. Tan M, Kim SH. Does PCOS Increase Insulin Resistance Above and Beyond Obesity? Endocrinol Metab Synd 3:142. doi: 10.4172/2161-1017.1000142